Vertex Pharmaceuticals. has filed a patent for modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). The patent also covers pharmaceutical compositions containing these modulators, methods of treating cystic fibrosis using them, and processes for making the modulators. The patent claims a specific compound and its derivatives that can be used as CFTR modulators. GlobalData’s report on Vertex Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vertex Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Vertex Pharmaceuticals's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Modulators of cystic fibrosis transmembrane conductance regulator (cftr)
A recently filed patent (Publication Number: US20230312616A1) describes a compound of Formula (1) and its various derivatives and salts. The compound is intended for use in the treatment of cystic fibrosis. The patent claims that the compound can be modified by replacing certain carbon atoms and methyl groups with silicon atoms, as well as replacing methylene and methine groups with specific groups. These modifications aim to enhance the compound's effectiveness in treating cystic fibrosis.
The patent also claims that the compound can be further modified by replacing carbon atoms at specific positions with silicon atoms. Additionally, methyl groups at certain positions can be replaced with various groups, including —Si(R)3 groups, —Si(R)2(OR) groups, and —Si(R)(OR)2 groups. Furthermore, methylene groups at specific positions can be replaced with >Si(R)2 groups and >Si(R)(OR) groups. The methine group at position 11 can also be replaced with -Si(R) groups and -Si(OR) groups. These modifications can be applied to the compound and its derivatives and salts.
The patent further describes a pharmaceutical composition that includes the compound of Formula (1), its derivatives, and salts, along with a pharmaceutically acceptable carrier. The composition may also include additional compounds, such as Compound (II) and Compound (III), and their derivatives and salts. This composition is intended for use in the treatment of cystic fibrosis.
The patent also discloses a method of preparing the compound of Formula (1), its derivatives, and salts. The method involves reacting a compound of Formula (F-1) or a salt thereof with a compound of Formula (G-1) or a salt thereof to generate the desired compound. The reaction results in the replacement of specific carbon atoms and methyl groups with silicon atoms and various other groups.
In summary, the filed patent describes a compound of Formula (1) and its derivatives and salts for the treatment of cystic fibrosis. The patent claims that the compound can be modified by replacing certain atoms and groups, and a pharmaceutical composition containing the compound and additional compounds. The patent also discloses a method of preparing the compound.
To know more about GlobalData’s detailed insights on Vertex Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
